Le Lézard
Classified in: Health
Subjects: SLS, ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2024


Zinzino group revenue increased with a total of 39 %, compared with the previous year.

GOTHENBURG, Sweden, Sept. 4, 2024 /PRNewswire/ -- The revenue in August for Zinzino's sales markets increased by 38 % and amounted to SEK 166.4 (120.6) million. Faun Pharma's external sales increased by 58 % and amounted to SEK 12.3 (7.8) million. Overall, the Group increased revenues by 39 % to SEK 178.7 (128.4) million compared with the previous year.

Accumulated revenue for January ? August 2024 increased by 21 % to SEK 1309.4 (1080.3) million.

Revenues were distributed as follows:

Regions,MSEK

24-Aug

23-Aug

Change

YTD 2024

YTD 2023

Change

The Nordics

23.7

23.6

0 %

188.6

191.6

-2 %

Central Europe

45.5

33.4

36 %

345.4

266.0

30 %

East Europe

31.3

27.1

15 %

251.9

249.4

1 %

South & West Europe

33.3

19,0

75 %

226.9

153.8

48 %

The Baltics

6.7

6.6

2 %

62.2

58.5

6 %

North America

15.5

6.9

125 %

113.6

53.3

113 %

Asia-Pacific

9.1

3.2

184 %

37.3

37.3

0 %

Africa

1.3

0.8

63 %

9.6

9.0

7 %

Zinzino

166.4

120.6

38 %

1 235,5

1018.9

21 %

Faun Pharma

12.3

7.8

58 %

73.9

61.4

20 %

Zinzino Group

178.7

128.4

39 %

1309.4

1080.3

21 %

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge: [email protected]

Certified Adviser: Carnegie Investment Bank AB (publ)

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--preliminary-sales-report-august-2024,c4033003

The following files are available for download:

https://mb.cision.com/Public/10976/4033003/96b7161a741fabed.pdf

2408 Pressrelease Salesreport EN


These press releases may also interest you

at 17:40
Blood Market to Grow by USD 2.6 Billion (2024-2028), Report on AI-Driven Market Transformation and Growth in Hospitals and Blood Banks - Technavio
Report with the AI impact on market trends - The global blood market  size is estimated to grow by USD 2.60 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  5.94%  during the forecast period. Rising number...

at 17:30
Analytical Standards Market to Grow by USD 657.8 Million (2024-2028), Report on AI-Powered Market Evolution and Life Science Industry Growth - Technavio
Report on how AI is driving market transformation - The global analytical standards market size is estimated to grow by USD 657.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  6.78%  during the forecast...

at 17:19
Award-Winning Journalist Linda Villarosa Discussed Link Between Health and Racism at Foundation for a Healthy St. Petersburg
As part of the Foundation's popular Speakers Who Inspire series, Villarosa shared insights from her groundbreaking book, Under the Skin: The Hidden Toll of Racism on American...

at 17:10
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with...

at 17:05
Nova Leap Health Corp. provides update on Special Meeting
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, announces that the Special Meeting of shareholders (the "Meeting") previously scheduled to be held on December 17, 2024 has been rescheduled to January...

at 16:30
Edesa Biotech Reports Fiscal Year 2024 Results
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update...

More news about Health...


News published on and distributed by: